Standout Papers

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study 2016 2026 2019 2022 1.1k
  1. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study (2016)
    Rita Nanda, Laura Q.M. Chow et al. Journal of Clinical Oncology
  2. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial (2016)
    Kei Muro, Hyun Cheol Chung et al. The Lancet Oncology
  3. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018)
    Ranee Mehra, Tanguy Y. Seiwert et al. British Journal of Cancer

Immediate Impact

8 by Nobel laureates 14 from Science/Nature 72 standout
Sub-graph 1 of 18

Citing Papers

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
2023 Standout
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 Standout

Works of Ravit Geva being referenced

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
2016 Standout
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
2013

Author Peers

Author Last Decade Papers Cites
Ravit Geva 4002 647 1572 1174 133 5.2k
Wei Qiao 2663 440 1244 1238 157 5.5k
Yosuke Togashi 4091 664 2276 1892 152 6.2k
Magali Svrcek 3134 1187 1166 483 130 4.6k
Talia Golan 5148 715 1607 1014 168 6.9k
Xavier Sagaert 2097 1366 968 772 117 4.8k
Miao‐Zhen Qiu 2477 577 1509 394 164 4.7k
Simon Pernot 2156 415 1031 921 97 3.4k
Aatur D. Singhi 3764 449 1061 629 218 6.5k
Neil H. Segal 5675 1209 2147 2700 147 8.4k
Fadi Braiteh 4087 551 1972 1126 73 5.5k

All Works

Loading papers...

Rankless by CCL
2026